See the latest news and media coverage for Enorama Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Pharmaceutical company developing and commercializing oral nicotine products
enoramapharma.comLast updated
In short: Enorama Pharma challenged the FDA in court after a refuse-to-file order for its nicotine pouches led to significant financial distress.
The FDA has completed its reconsideration and upheld its original decision. The company continues legal proceedings at the United States District Court for the District of Columbia.
The resignation is for personal reasons. Amy Walker assumes the role of acting CEO with immediate effect.
The meeting resolved no dividend, carried forward profits, and authorized share issuances.
The purchase price is 100,000 EUR. The deal includes marketing authorizations and patents.
Enorama Pharma, which manufactures medical chewing gums, reports an operating result of minus 11.7 million kronor for the second quarter of 2026 (minus 15.3).
Close Agenda: Rusta, Zalando and definitive KPI. Thursday's highlights with Noel Hermansson The equity in Enorama Pharma, a company active in tobacco-free white snus, is below...
Enorama Pharma AB (publ) ("Enorama Pharma" or "the Company") announces today an organizational change in the board and management group. The board has, in agreement with managing director Daniel Schröder...
Enorama Pharma Inc. filed a lawsuit against the U.S. Food and Drug Administration in federal court in Washington, D.C., alleging the agency unlawfully imposed costly...
Track Enorama Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Enorama Pharma and other trending companies.